Isolation of Cryptococcus Species from Sputum of Patients with Presumptive Pulmonary Tuberculosis Attending a Referral Hospital in Cross River State, Nigeria

سال انتشار: 1404
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 4

فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_JOMMID-14-2_010

تاریخ نمایه سازی: 22 مهر 1405

چکیده مقاله:

Introduction: The differential diagnosis of pulmonary tuberculosis (TB) and fungal infections is important in influencing treatment strategies and enhancing therapeutic success. Therefore, this study aimed to investigate the prevalence of Cryptococcus species among presumptive tuberculosis patients in a referral hospital in Nigeria. Methods: This cross-sectional, hospital-based study was carried out between October ۲۰۲۴ and January ۲۰۲۵. A total of ۱۷۴ sputum samples were tested for the presence of Mycobacterium tuberculosis using Ziehl-Neelsen staining and the molecular GeneXpert MTB/RIF assay; Cryptococcus species were isolated by culture on Sabouraud Dextrose Agar (SDA) and presumptively identified as encapsulated yeasts using India ink staining. Results: None of the samples (۰%) obtained from presumptive tuberculosis patients were positive for M. tuberculosis, highlighting the importance of investigating other pathogens, such as Cryptococcus species, in patients presenting with TB-like symptoms. Cryptococcus species were isolated from ۲۱ of ۱۷۴ patients, giving an overall prevalence of ۱۲.۱%. A significant gender disparity was observed, with females showing a much higher prevalence (۳۵.۲%) compared with males (۱.۷%). Age was not significantly associated with infection status, although individuals aged ۵۰–۵۹ years had the highest age-specific prevalence, with ۴ out of ۲۰ patients (۲۰.۰%) testing positive. Statistical analysis confirmed the significant gender difference (χ² = ۳۹.۴۲۶, P < ۰.۰۰۱), while the association with age was not statistically significant (Fisher–Freeman–Halton exact test statistic = ۷.۶۸۱, P = ۰.۱۹۹). No Cryptococcus isolates were recovered from participants aged ۱–۹ years, ۴۰–۴۹ years, and ≥ ۶۰ years. Conclusion: The moderate prevalence of Cryptococcus species observed in this study suggests their potential as a lower respiratory tract pathogen in presumptive tuberculosis patients. The results of this study show the need to integrate fungal screening into routine diagnostic protocols for tuberculosis, especially where fungi such as Cryptococcus species are often neglected.

نویسندگان

Chinedu Nkem Awujo

Department of Microbiology, Faculty of Biosciences, Federal University Wukari, P.M.B. ۱۰۲۰, Wukari, Taraba State, Nigeria

Emmanuel Gaina

Department of Microbiology, Faculty of Biosciences, Federal University Wukari, P.M.B. ۱۰۲۰, Wukari, Taraba State, Nigeria

Samuel Brown

Department of Microbiology, Faculty of Biosciences, Federal University Wukari, P.M.B. ۱۰۲۰, Wukari, Taraba State, Nigeria

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • World Health Organization. WHO fungal priority pathogens list to guide ...
  • Lionakis MS, Drummond RA, Hohl TM. Immune responses to human ...
  • Lass-Flörl C, Kanj SS, Govender NP, Thompson GR ۳rd, Ostrosky-Zeichner ...
  • Machado M, Fortún J, Muñoz P. Invasive aspergillosis: a comprehensive ...
  • Ekeng BE, Oladele RO, Emanghe UE, Ochang EA, Mirabeau TY. ...
  • Rajasingham R, Govender NP, Jordan A, Loyse A, Shroufi A, ...
  • Weissferdt A. Infectious lung disease. In: Diagnostic thoracic pathology. Cham: ...
  • Amiri Fahliyani S, Rastegari AA, Yadav N, Yadav AN. Human ...
  • Oladele R, Otu AA, Olubamwo O, Makanjuola OB, Ochang EA, ...
  • Muni S, Rajpal K, Kumar R, Kumari R, Sinha R, ...
  • Prasad R, Singh A, Sharma S, Patel D, Tiwari S, ...
  • Rebuma T, Parmar RB, Parmar BC, Pal M. Emerging fungal ...
  • Ekeng BE, Davies AA, Osaigbovo II, Warris A, Oladele RO, ...
  • Mereškevičienė R, Danila E. The adverse effects of tuberculosis treatment: ...
  • World Health Organization. Global tuberculosis report ۲۰۲۵ [Internet]. Geneva: World ...
  • National Population Commission (NPC), ICF. Nigeria Demographic and Health Survey ...
  • Nigerian Meteorological Agency. Cross River State farmer weather guide [Internet]. ...
  • World Health Organization. WHO operational handbook on tuberculosis. Module ۳: ...
  • Clinical and Laboratory Standards Institute. Principles and procedures for detection ...
  • Njovu IK, Musinguzi B, Mwesigye J, Kassaza K, Turigurwa J, ...
  • Bitew A, Bati S. Profiling of potential pulmonary fungal pathogens ...
  • Cioboata R, Balteanu MA, Osman A, Vlasceanu SG, Zlatian OM, ...
  • Edwards HM, Cogliati M, Kwenda G, Fisher MC. The need ...
  • May RC, Stone NR, Wiesner DL, Bicanic T, Nielsen K. ...
  • Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate ...
  • Nnadi NE, Carter DA. Climate change and the emergence of ...
  • Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, ...
  • Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for ...
  • Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence ...
  • Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, ...
  • Perfect JR. The antifungal pipeline: a reality check. Nat Rev ...
  • Niazi-Ali S, Atherton GT, Walczak M, Denning DW. Drug-drug interaction ...
  • World Health Organization. WHO fungal priority pathogens list to guide ...
  • Lionakis MS, Drummond RA, Hohl TM. Immune responses to human ...
  • Lass-Flörl C, Kanj SS, Govender NP, Thompson GR ۳rd, Ostrosky-Zeichner ...
  • Machado M, Fortún J, Muñoz P. Invasive aspergillosis: a comprehensive ...
  • Ekeng BE, Oladele RO, Emanghe UE, Ochang EA, Mirabeau TY. ...
  • Rajasingham R, Govender NP, Jordan A, Loyse A, Shroufi A, ...
  • Weissferdt A. Infectious lung disease. In: Diagnostic thoracic pathology. Cham: ...
  • Amiri Fahliyani S, Rastegari AA, Yadav N, Yadav AN. Human ...
  • Oladele R, Otu AA, Olubamwo O, Makanjuola OB, Ochang EA, ...
  • Muni S, Rajpal K, Kumar R, Kumari R, Sinha R, ...
  • Prasad R, Singh A, Sharma S, Patel D, Tiwari S, ...
  • Rebuma T, Parmar RB, Parmar BC, Pal M. Emerging fungal ...
  • Ekeng BE, Davies AA, Osaigbovo II, Warris A, Oladele RO, ...
  • Mereškevičienė R, Danila E. The adverse effects of tuberculosis treatment: ...
  • World Health Organization. Global tuberculosis report ۲۰۲۵ [Internet]. Geneva: World ...
  • National Population Commission (NPC), ICF. Nigeria Demographic and Health Survey ...
  • Nigerian Meteorological Agency. Cross River State farmer weather guide [Internet]. ...
  • World Health Organization. WHO operational handbook on tuberculosis. Module ۳: ...
  • Clinical and Laboratory Standards Institute. Principles and procedures for detection ...
  • Njovu IK, Musinguzi B, Mwesigye J, Kassaza K, Turigurwa J, ...
  • Bitew A, Bati S. Profiling of potential pulmonary fungal pathogens ...
  • Cioboata R, Balteanu MA, Osman A, Vlasceanu SG, Zlatian OM, ...
  • Edwards HM, Cogliati M, Kwenda G, Fisher MC. The need ...
  • May RC, Stone NR, Wiesner DL, Bicanic T, Nielsen K. ...
  • Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate ...
  • Nnadi NE, Carter DA. Climate change and the emergence of ...
  • Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, ...
  • Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for ...
  • Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence ...
  • Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, ...
  • Perfect JR. The antifungal pipeline: a reality check. Nat Rev ...
  • Niazi-Ali S, Atherton GT, Walczak M, Denning DW. Drug-drug interaction ...
  • نمایش کامل مراجع